Marinomed sets offer price at 75 Euro per share

299,000 new shares (equals to around EUR 22.4 million) placed with investors (incl. 39,000 new shares from the over-allotment/Greenshoe) - Gross proceeds amounts to EUR 19.5 million (excl. over-allotments/Greenshoe)

Marinomed Biotech AG (“Marinomed” or the “company”) has set the Offer Price for new shares of the company in connection with its IPO at 75 Euro per share.

In total, 299,000 new bearer shares were placed with investors. These consist of 260,000 shares from the base offer and 39,000 shares due to over-allotments. Assuming full exercise of the greenshoe option, gross proceeds will amount to EUR 22.4 million. The proceeds from the IPO shall be used primarily to fund the Pivotal Phase III study of Budesolv, Phase II and Phase III studies of Tacrosolv as well as the extension of the Carragelose® OTC platform.

Based on the total number of 1,299,000 shares (assuming a full exercise of the greenshoe option) and the Offer Price of EUR 75 per share, the market capitalization of Marinomed amounts to approximately EUR 97.4 million. The free float is around 31% (thereof around 22% by from new investors in the IPO). In case all convertible bonds are converted to new shares of Marinomed Biotech AG, the free float increases to 39%. The expected settlement date and first trading day is 1 February 2019. From this date the Marinomed shares are intended to be traded under the symbol "MARI" on the official market (prime market segment) of the Vienna Stock Exchange.

The Marinomed Management Board has committed itself to a lock-up period of 36 months, almost all of the other existing shareholders and the company itself to a lock-up period of 12 months.

The transaction meets the requirements of a qualified public offer in accordance with the terms and conditions of the convertible bonds issued in 2017 that are traded on the Third Market of the Vienna Stock Exchange. Convertible bondholders are thus entitled to convert their bonds into new shares of Marinomed Biotech AG in accordance with the terms and conditions of the convertible bond. The conversion period starts with the settlement day (expected to be 1 February 2019) and will run until 14 February 2019, 16:00 CET. The conversion price is 40.8676 Euro.

In this transaction, Marinomed was supported by Erste Group Bank AG as Sole Global Coordinator and goetzpartners securities Limited as Co-Lead Manager.

About Marinomed Biotech AG

Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the development of innovative products derived from patent protected technology platforms to treat respiratory and ophthalmic conditions. The Carragelose® platform comprises innovative patent protected products targeting viral infections of the respiratory tract. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold in more than 30 countries around the world in collaboration with international partners. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose. Further information is available at

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)